A Novel Tumor Glycolysis Inhibitor: 4-Methylumbelliferone

IF 0.6 4区 医学 Q4 CHEMISTRY, MEDICINAL
Zi-Yao Li, Qin Yang, Xiao-Ge Cheng, Yan-Li Zhou, Xiang-Ling Piao, Li Qiu, Bo-Jun Zhou, Song-Tao Wu
{"title":"A Novel Tumor Glycolysis Inhibitor: 4-Methylumbelliferone","authors":"Zi-Yao Li, Qin Yang, Xiao-Ge Cheng, Yan-Li Zhou, Xiang-Ling Piao, Li Qiu, Bo-Jun Zhou, Song-Tao Wu","doi":"10.1177/09731296231206300","DOIUrl":null,"url":null,"abstract":"Background and Objectives 4-Methylumbelliferone (4-MU) is a coumarin compound that can be extracted from the medicinal plant with anti-cancer properties, Smilax china L. In recent years, studies have revealed its potential as an anti-tumor and anti-metastasis drug with promising effects in cancer treatment. Despite an increase in research on the metabolic patterns of tumor cells, no prior research has suggested that 4-MU inhibits tumor proliferation by blocking glycolysis. This thesis presents evidence that 4-MU binds to proteins involved in glycolysis, thus mediating its anti-tumor effects. Materials and Methods Network pharmacology, transcriptomics, and molecular docking were utilized to forecast the potential targets and probable pathways of 4-MU’s anti-cancer activity, and the affinity of 4-MU towards potential targets was discovered using microscale thermophoresis (MST) detection. Results The results of transcriptome analysis brought to light that the genes with differential expressions were primarily enriched in metabolic pathways, including glycolysis-related proteins. Using network pharmacology and molecular docking, our study identified Heat Shock Protein 90 Alpha Family Class A Member 1 (Hsp90AA1), mitochondria, phosphoglycerate kinase 2 (PGK2), glycerol-3-phosphate dehydrogenase (GPD2), and glucose-6-phosphate isomerase (GPI) as potential targets of 4-MU. The strong binding affinity between 4-MU and these proteins was confirmed by the MST assay. Conclusion The findings indicate that 4-MU can hinder glycolysis by binding to glycolysis-associated proteins such as Hsp90AA1, PGK2, GPD2, and GPI. This results in the prevention of the energy supply to the tumor tissue, which ultimately curbs tumor growth, thereby demonstrating its anti-tumor properties. These results conclude that 4-MU has the capacity to be a novel glycolysis inhibitor for cancer treatment. Moreover, the identification of these glycolysis-associated proteins as possible targets for cancer therapy offers new avenues for research in the field of cancer treatment, thus providing further valuable evidence for the anti-cancer mechanism of 4-MU.","PeriodicalId":19895,"journal":{"name":"Pharmacognosy Magazine","volume":"213 ","pages":"0"},"PeriodicalIF":0.6000,"publicationDate":"2023-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacognosy Magazine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/09731296231206300","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background and Objectives 4-Methylumbelliferone (4-MU) is a coumarin compound that can be extracted from the medicinal plant with anti-cancer properties, Smilax china L. In recent years, studies have revealed its potential as an anti-tumor and anti-metastasis drug with promising effects in cancer treatment. Despite an increase in research on the metabolic patterns of tumor cells, no prior research has suggested that 4-MU inhibits tumor proliferation by blocking glycolysis. This thesis presents evidence that 4-MU binds to proteins involved in glycolysis, thus mediating its anti-tumor effects. Materials and Methods Network pharmacology, transcriptomics, and molecular docking were utilized to forecast the potential targets and probable pathways of 4-MU’s anti-cancer activity, and the affinity of 4-MU towards potential targets was discovered using microscale thermophoresis (MST) detection. Results The results of transcriptome analysis brought to light that the genes with differential expressions were primarily enriched in metabolic pathways, including glycolysis-related proteins. Using network pharmacology and molecular docking, our study identified Heat Shock Protein 90 Alpha Family Class A Member 1 (Hsp90AA1), mitochondria, phosphoglycerate kinase 2 (PGK2), glycerol-3-phosphate dehydrogenase (GPD2), and glucose-6-phosphate isomerase (GPI) as potential targets of 4-MU. The strong binding affinity between 4-MU and these proteins was confirmed by the MST assay. Conclusion The findings indicate that 4-MU can hinder glycolysis by binding to glycolysis-associated proteins such as Hsp90AA1, PGK2, GPD2, and GPI. This results in the prevention of the energy supply to the tumor tissue, which ultimately curbs tumor growth, thereby demonstrating its anti-tumor properties. These results conclude that 4-MU has the capacity to be a novel glycolysis inhibitor for cancer treatment. Moreover, the identification of these glycolysis-associated proteins as possible targets for cancer therapy offers new avenues for research in the field of cancer treatment, thus providing further valuable evidence for the anti-cancer mechanism of 4-MU.
一种新的肿瘤糖酵解抑制剂:4- methylumbellliferone
背景与目的4- methylumbellliferone (4-MU)是一种从具有抗癌作用的药用植物菝葜中提取的香豆素类化合物,近年来研究表明其具有抗肿瘤和抗转移的潜力,在癌症治疗中具有良好的效果。尽管对肿瘤细胞代谢模式的研究越来越多,但之前没有研究表明4-MU通过阻断糖酵解来抑制肿瘤增殖。本文提出证据表明,4-MU与参与糖酵解的蛋白质结合,从而介导其抗肿瘤作用。材料与方法利用网络药理学、转录组学、分子对接等方法预测4-MU抗癌活性的潜在靶点和可能通路,并利用微尺度热泳术(MST)检测发现4-MU对潜在靶点的亲和力。结果转录组分析结果表明,差异表达基因主要富集于代谢途径,包括糖酵解相关蛋白。通过网络药理学和分子对接,我们的研究确定了热休克蛋白90 α家族A类成员1 (Hsp90AA1)、线粒体、磷酸甘油酸激酶2 (PGK2)、甘油-3-磷酸脱氢酶(GPD2)和葡萄糖-6-磷酸异构酶(GPI)是4-MU的潜在靶点。MST实验证实了4-MU与这些蛋白之间的强结合亲和力。结论4-MU通过与糖酵解相关蛋白Hsp90AA1、PGK2、GPD2和GPI结合而抑制糖酵解。这导致阻止肿瘤组织的能量供应,最终抑制肿瘤生长,从而显示其抗肿瘤特性。这些结果表明,4-MU有能力成为一种新的糖酵解抑制剂,用于癌症的治疗。此外,这些糖酵解相关蛋白作为癌症治疗的可能靶点,为癌症治疗领域的研究提供了新的途径,从而为4-MU的抗癌机制提供了进一步有价值的证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmacognosy Magazine
Pharmacognosy Magazine CHEMISTRY, MEDICINAL-
CiteScore
1.87
自引率
0.00%
发文量
37
审稿时长
3 months
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信